Shopping Cart 0
Cart Subtotal
AED 0

Summit Therapeutics Plc (SUMM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

Summit Therapeutics Plc (Summit), formerly Summit Corp Plc is a clinical-stage drug discovery and development company that offer therapies. The company conducts research and development on the treatment of rare diseases and infectious diseases including duchenne muscular dystrophy and the infectious disease caused by the bacteria C difficile. It develops ridinilazole, an antibiotic that has the potential to treat CDI and reduce disease recurrence. Summit undertakes utrophin modulation program for duchenne muscular dystrophy. The company also develops novel antibiotic program for the treatment of superbug C. difficile. It operates through other pharmaceutical companies and charity foundations and parent advocacy groups. The company operates through its office located in Cambridge, the US. Summit is headquartered in Abingdon, the UK.

Summit Therapeutics Plc (SUMM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Summit Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Summit Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018 10

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Summit (Oxford) Enters into Contract with Biomedical Advanced Research and Development Authority 13

Summit Therapeutics Enters into Agreement with University of Oxford 14

Licensing Agreements 15

Summit Therapeutics Enters into Licensing Agreement with Eurofarma Laboratorios 15

Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 16

Roche Expands its Licensing Agreement with Discuva 17

Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 18

Equity Offering 19

Summit Therapeutics Plans to Raise up to USD225 Million in Public offering of Securities 19

Summit Therapeutics Raises USD21.3 Million in Private Placement of Shares 20

Summit Therapeutics Raises USD20.1 Million in Public Offering of Shares 22

Summit Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants 24

Summit Therapeutics Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 25

Summit Therapeutics Completes Initial Public Offering of American Depositary Shares 26

Summit Therapeutics Raises USD36.6 Million in Private Placement of Shares 28

Summit Completes Private Placement Of Shares For USD 34.4 Million 29

Summit Completes Private Placement Of Shares For USD 1.6 Million 30

Summit Completes Private Placement Of Shares For USD 7 Million 31

Summit Completes Private Placement Of Shares For USD 0.1 Million 32

Summit Announces Private Placement Of Shares For USD 8 Million 33

Acquisition 34

Summit Therapeutics Acquires Discuva for USD13.3 Million 34

Summit Acquires MuOx for USD5.3 Million 35

Summit Therapeutics Plc-Key Competitors 36

Summit Therapeutics Plc-Key Employees 37

Summit Therapeutics Plc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 40

Financial Announcements 40

Sep 20, 2018: Summit Therapeutics reports financial results for the second quarter ended 31 July 2018 and operational progress 40

Jun 05, 2018: Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational Progress 46

Apr 11, 2018: Summit Therapeutics Reports Financial Results for the Fiscal Year Ended 31 January 2018 47

Apr 11, 2018: Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 and Operational Progress 54

Dec 06, 2017: Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational Progress 55

Aug 31, 2017: Summit Therapeutics Reports Financial Results For The Second Quarter And Half Year Ended 31 July 2017 And Operational Progress 57

Jun 14, 2017: Summit Therapeutics Reports Financial Results For The First Quarter Ended 30 April 2017 And Operational Progress 60

Mar 29, 2017: Summit Therapeutics Reports 4th Quarter and Year End Financial Results and Operational Progress 62

Corporate Communications 63

May 23, 2017: Summit Announces Key Appointments to Strengthen Research & Development Team 63

Jan 18, 2017: Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development 65

Government and Public Interest 66

Jul 10, 2018: Summit Therapeutics Wins up to USD 4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics 66

Product News 67

09/05/2018: Summit nominates new mechanism antibiotic SMT-571 as its lead clinical candidate for the treatment of gonorrhoea 67

04/23/2018: Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018 68

Mar 13, 2018: Summit's Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea 69

Clinical Trials 70

Nov 20, 2017: Summit Completes Initial 24 Weeks Of Dosing Of Ezutromid In Patients With DMD In Phaseout DMD Clinical Trial 70

Oct 04, 2017: Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS Congress 71

Sep 25, 2017: Summit Joins cTAP In Collaborative Effort To Enhance The Development Of Utrophin Modulators And Other Treatments For Duchenne Muscular Dystrophy 74

Jun 22, 2017: Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress 75

May 15, 2017: Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD 76

Mar 27, 2017: Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients with DMD 77

Other Significant Developments 78

Sep 06, 2018: Summit Discovers multiple new mechanism antibiotics against novel ESKAPE pathogen targets 78

Mar 30, 2017: Summit Therapeutics: Change of Registered Office 79

Mar 30, 2017: Summit Announces Change Of Registered Company Address 80

Appendix 81

Methodology 81

About GlobalData 81

Contact Us 81

Disclaimer 81


List Of Figure

List of Figures

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Summit Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Summit Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Summit Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Summit Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018 10

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Summit (Oxford) Enters into Contract with Biomedical Advanced Research and Development Authority 13

Summit Therapeutics Enters into Agreement with University of Oxford 14

Summit Therapeutics Enters into Licensing Agreement with Eurofarma Laboratorios 15

Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 16

Roche Expands its Licensing Agreement with Discuva 17

Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 18

Summit Therapeutics Plans to Raise up to USD225 Million in Public offering of Securities 19

Summit Therapeutics Raises USD21.3 Million in Private Placement of Shares 20

Summit Therapeutics Raises USD20.1 Million in Public Offering of Shares 22

Summit Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants 24

Summit Therapeutics Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 25

Summit Therapeutics Completes Initial Public Offering of American Depositary Shares 26

Summit Therapeutics Raises USD36.6 Million in Private Placement of Shares 28

Summit Completes Private Placement Of Shares For USD 34.4 Million 29

Summit Completes Private Placement Of Shares For USD 1.6 Million 30

Summit Completes Private Placement Of Shares For USD 7 Million 31

Summit Completes Private Placement Of Shares For USD 0.1 Million 32

Summit Announces Private Placement Of Shares For USD 8 Million 33

Summit Therapeutics Acquires Discuva for USD13.3 Million 34

Summit Acquires MuOx for USD5.3 Million 35

Summit Therapeutics Plc, Key Competitors 36

Summit Therapeutics Plc, Key Employees 37

Summit Therapeutics Plc, Other Locations 38

Summit Therapeutics Plc, Subsidiaries 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Summit Therapeutics Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Summit Therapeutics Plc (Summit), formerly Summit Corp Plc is a clinical-stage drug discovery and development company that offer therapies. The company conducts research and development on the treatment of rare diseases and infectious diseases including duchenne muscular dystrophy and the infectious disease caused by the bacteria C difficile. It develops ridinilazole, an antibiotic that has the potential to treat CDI and reduce disease recurrence. Summit undertakes utrophin modulation program for duchenne muscular dystrophy. The company also develops novel antibiotic program for the treatment of superbug C. difficile. It operates through other pharmaceutical companies and charity foundations and parent advocacy groups. The company operates through its office located in Cambridge, the US. Summit is headquartered in Abingdon, the UK.

Summit Therapeutics Plc (SUMM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Summit Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Summit Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018 10

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Summit (Oxford) Enters into Contract with Biomedical Advanced Research and Development Authority 13

Summit Therapeutics Enters into Agreement with University of Oxford 14

Licensing Agreements 15

Summit Therapeutics Enters into Licensing Agreement with Eurofarma Laboratorios 15

Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 16

Roche Expands its Licensing Agreement with Discuva 17

Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 18

Equity Offering 19

Summit Therapeutics Plans to Raise up to USD225 Million in Public offering of Securities 19

Summit Therapeutics Raises USD21.3 Million in Private Placement of Shares 20

Summit Therapeutics Raises USD20.1 Million in Public Offering of Shares 22

Summit Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants 24

Summit Therapeutics Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 25

Summit Therapeutics Completes Initial Public Offering of American Depositary Shares 26

Summit Therapeutics Raises USD36.6 Million in Private Placement of Shares 28

Summit Completes Private Placement Of Shares For USD 34.4 Million 29

Summit Completes Private Placement Of Shares For USD 1.6 Million 30

Summit Completes Private Placement Of Shares For USD 7 Million 31

Summit Completes Private Placement Of Shares For USD 0.1 Million 32

Summit Announces Private Placement Of Shares For USD 8 Million 33

Acquisition 34

Summit Therapeutics Acquires Discuva for USD13.3 Million 34

Summit Acquires MuOx for USD5.3 Million 35

Summit Therapeutics Plc-Key Competitors 36

Summit Therapeutics Plc-Key Employees 37

Summit Therapeutics Plc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 40

Financial Announcements 40

Sep 20, 2018: Summit Therapeutics reports financial results for the second quarter ended 31 July 2018 and operational progress 40

Jun 05, 2018: Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational Progress 46

Apr 11, 2018: Summit Therapeutics Reports Financial Results for the Fiscal Year Ended 31 January 2018 47

Apr 11, 2018: Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2018 and Operational Progress 54

Dec 06, 2017: Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational Progress 55

Aug 31, 2017: Summit Therapeutics Reports Financial Results For The Second Quarter And Half Year Ended 31 July 2017 And Operational Progress 57

Jun 14, 2017: Summit Therapeutics Reports Financial Results For The First Quarter Ended 30 April 2017 And Operational Progress 60

Mar 29, 2017: Summit Therapeutics Reports 4th Quarter and Year End Financial Results and Operational Progress 62

Corporate Communications 63

May 23, 2017: Summit Announces Key Appointments to Strengthen Research & Development Team 63

Jan 18, 2017: Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development 65

Government and Public Interest 66

Jul 10, 2018: Summit Therapeutics Wins up to USD 4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics 66

Product News 67

09/05/2018: Summit nominates new mechanism antibiotic SMT-571 as its lead clinical candidate for the treatment of gonorrhoea 67

04/23/2018: Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018 68

Mar 13, 2018: Summit's Infectious Diseases Technology Platform Yields Novel Antibiotics with Potential in Global Fight Against Gonorrhoea 69

Clinical Trials 70

Nov 20, 2017: Summit Completes Initial 24 Weeks Of Dosing Of Ezutromid In Patients With DMD In Phaseout DMD Clinical Trial 70

Oct 04, 2017: Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS Congress 71

Sep 25, 2017: Summit Joins cTAP In Collaborative Effort To Enhance The Development Of Utrophin Modulators And Other Treatments For Duchenne Muscular Dystrophy 74

Jun 22, 2017: Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress 75

May 15, 2017: Summit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMD 76

Mar 27, 2017: Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients with DMD 77

Other Significant Developments 78

Sep 06, 2018: Summit Discovers multiple new mechanism antibiotics against novel ESKAPE pathogen targets 78

Mar 30, 2017: Summit Therapeutics: Change of Registered Office 79

Mar 30, 2017: Summit Announces Change Of Registered Company Address 80

Appendix 81

Methodology 81

About GlobalData 81

Contact Us 81

Disclaimer 81


List Of Figure

List of Figures

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Summit Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Summit Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Summit Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Summit Therapeutics Plc, Medical Devices Deals, 2012 to YTD 2018 10

Summit Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Summit (Oxford) Enters into Contract with Biomedical Advanced Research and Development Authority 13

Summit Therapeutics Enters into Agreement with University of Oxford 14

Summit Therapeutics Enters into Licensing Agreement with Eurofarma Laboratorios 15

Sarepta Therapeutics Enters into Licensing Agreement with Summit Therapeutics 16

Roche Expands its Licensing Agreement with Discuva 17

Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 18

Summit Therapeutics Plans to Raise up to USD225 Million in Public offering of Securities 19

Summit Therapeutics Raises USD21.3 Million in Private Placement of Shares 20

Summit Therapeutics Raises USD20.1 Million in Public Offering of Shares 22

Summit Therapeutics Raises Funds in Private Placement of Shares upon Exercise of Warrants 24

Summit Therapeutics Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 25

Summit Therapeutics Completes Initial Public Offering of American Depositary Shares 26

Summit Therapeutics Raises USD36.6 Million in Private Placement of Shares 28

Summit Completes Private Placement Of Shares For USD 34.4 Million 29

Summit Completes Private Placement Of Shares For USD 1.6 Million 30

Summit Completes Private Placement Of Shares For USD 7 Million 31

Summit Completes Private Placement Of Shares For USD 0.1 Million 32

Summit Announces Private Placement Of Shares For USD 8 Million 33

Summit Therapeutics Acquires Discuva for USD13.3 Million 34

Summit Acquires MuOx for USD5.3 Million 35

Summit Therapeutics Plc, Key Competitors 36

Summit Therapeutics Plc, Key Employees 37

Summit Therapeutics Plc, Other Locations 38

Summit Therapeutics Plc, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Summit Therapeutics Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.